We know scientists have busy schedules. 🤷 That's why we put together #ProstateCell News, an online publication and bi-weekly email newsletter covering the latest research into breast cancer and mammary cells. 📰 Subscribe here: bit.ly/4kkWMEu

This study demonstrated that leucine-rich repeat-containing G protein-coupled receptor 4 was overexpressed in #BenignProstaticHyperplasia and localized within the stromal and epithelial components of the prostate. Learn more: bit.ly/4zFPVwu

By exploring emerging frontiers including neuroendocrine transdifferentiation, #nanobiotechnology, and liquid biopsy, this review proposes a roadmap for next-generation therapies aimed at sensitizing #ProstateCancer to immune recognition. 🗺️ Give it a read: bit.ly/3VMFZCN

Scientists dissect the multidimensional resistance mechanisms of #ProstateCancer to immune checkpoint inhibitors, ranging from myeloid cell plasticity to stromal stiffening. 📄 Abstract: bit.ly/3VMFZCN

💡 Transient receptor potential melastatin 4 (TRPM4) is a mechanistic driver and predictive biomarker of Acetalax response in prostate cancer 💡 A rationale for the clinical development of Acetalax for TRPM4-expressing and treatment-refractory prostate cancer is provided Read more: bit.ly/47TEtRR #ProstateCancer #CancerResearch

New in @CommsMedicine: study findings (@ucl and @UCLMS) highlight limitations in the representativeness of widely used #ProstateCancer cell lines and emphasize the importance of selecting models according to their clinical and molecular relevance. #OpenAccess 🔗 go.nature.com/4zyz26U

New study findings from researchers at @NotreDame identify PYGO2 as a #tumor-intrinsic regulator of castration resistance and antitumor #immunity in #ProstateCancer. 🔗 bit.ly/3VFHpPi

📢 Research in @iScience_CP investigated how physiologically relevant mechanical properties affect prostate cancer cells, demonstrating that mechanical microenvironmental cues substantially shape prostate cancer cell phenotypes. 🔗 bit.ly/4yuWEZP #ProstateCancer #OpenAccess

📢 New in @CellRepMed: Study findings identify EZH2-PI3K/mTORC1 signaling as a therapeutic vulnerability in phenotypically plastic #ProstateCancer and reveal the RNA-binding protein Tristetraprolin-associated regulatory programs as contributors to targeted therapy response. Read the #OpenAccess article here: bit.ly/4z8WoQf

Research in @PNASNews defines a hyperactive androgen receptor (AR)–LSD1 chromatin axis driven by minimal-length CAG repeats in AR, revealing a mechanistic link between inherited AR polymorphism, AR-mediated epigenetic-metabolic remodeling, and population-associated disparities in prostate cancer biology. Read more about the findings: bit.ly/4rJjZVm #ProstateCancer #AndrogenReceptor

Findings in a @NatureComms study identify nuclear receptor coactivator 6 as a potent tumor suppressor and a clinically relevant biomarker to identify prostate cancer patients most likely to benefit from EGFR-targeted therapy. Read the paper here📝 : go.nature.com/4rAchNd #ProstateCancer #EGFR

A new study reports that SSC185 reduced the MTT signal of PC-3 prostate cancer cells in a concentration- and time-dependent manner, with nutrient deprivation markedly enhancing its activity, indicating that the cellular nutritional context influences the response to the compound. Read the full paper: bit.ly/46TRHOa Led by first author Gisele Santos de Araújo and corresponding author Ana Jérsia Araujo at @UFDPar. #ProstateCancer #Oncology #DrugDiscovery

Restoring DPP4 expression via capsaicin suppresses prostate tumorigenesis in castration-resistant prostate cancer (CRPC) models, suggesting DPP4 could be a new target for CRPC. Read the study: bit.ly/3VAf4K9 Led by first author José María Mora-Rodríguez and corresponding author Inés Díaz-Laviada at the University of Alcalá and IDISCAM. #ProstateCancer #Oncology #DrugDiscovery

Researchers from Shaanxi Normal University identified BIRC6-AS1/BIRC6 as a significant contributor to abiraterone resistance in prostate cancer. They found depletion enhanced the sensitivity of prostate cancer cells to abiraterone in both in vitro and in vivo settings. Read the full paper: go.nature.com/4yUsDSX #ProstateCancer #CancerResearch #Oncology

A new study shows that PHD2-regulated degradation of HIFα contributes to PGC1α/ERRα-mediated prostate cancer suppression, providing a new component to the tumor-suppressive activity of the PGC1α/ERRα complex. Read the @Nature paper here: go.nature.com/4AqE9XS Led by first author Maider Fagoaga-Eugui and corresponding authors Arkaitz Carracedo and Edurne Berra at @upvehu, CIBERONC, and participating instiutions. #ProstateCancer #Oncology #CancerResearch

🧬 Exciting @Nature article delineates the etiologies and mutational processes that drive the genomic and clinical heterogeneity of #ProstateCancer. 👓 Read how they investigated the #genomes of 959 donors: go.nature.com/4he7snZ

🧪 Researchers at Soochow University compared magnetic nanomaterials to find the best #ExtracellularVesicle capture performance, which can enable early diagnosis and precision therapy in #ProstateCancer using urine samples. 👓 Read the article here: bit.ly/4j0qJLV

🦠 New research in @NatureCancer reveals that the gut-to-tumor translocation of N. glabratus contributes to endocrine resistance in #ProstateCancer. Read the #OpenAccess article here: go.nature.com/4xPyOaO

Read this interesting study from @ucl investigating how magnetic hyperthermia therapy induces cell death in #ProstateCancer and #melanoma cells. 👇 rsc.li/4xdwg5q

🦠Read about how the gut microbiota is linked to benign prostatic diseases like #ChronicPelvicPainSyndrome and #BenignProstaticHyperplasia in this review👇 bit.ly/4zXQbYq

Researchers including Alexandra Nukovic show that an O2-generating platform, Click O2-CryogelVAX, targeting the tumor-associated antigen prostatic acid phosphatase, enhances adaptive immune responses, and provides therapeutic benefits in a #ProstateCancer model. 🔗 bit.ly/46GmJsF